The use of immune globulin therapy appears to benefit children who experience acute heart failure caused by coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome, according to the findings of a case series recently published in Circulation.
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Evidence presented for delirium during COVID-19, post-illness neuropsychiatric consequences for SARS, MERS
The study will enroll 400 patients with symptomatic coronavirus disease 201.
Sociodemographic risk factors include male sex, deprivation, population density, ethnicity, obesity.
Second study shows no benefit versus standard of care in probability of negative conversion by 28 days.
TNF antagonists not associated with severe COVID-19 in patients with inflammatory bowel disease.
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Hydroxychloroquine alone or with azithromycin associated with abnormal electrocardiogram findings.
In series of 25 patients, 19 experienced improvement in clinical status by day 14; 11 were discharged.
